{
  "run_id": "RUN_20260203_174258_0a58abccb18d",
  "timestamp": "2026-02-03T19:27:26.850558",
  "document": "Fetal-Hydantoin-Syndrome.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/NLP4RARE/dev/Fetal-Hydantoin-Syndrome.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 2,
  "total_validated": 2,
  "total_rejected": 0,
  "total_investigational": 0,
  "drugs": [
    {
      "matched_text": "phenytoin",
      "preferred_name": "phenytoin",
      "brand_name": "PHENYTOIN",
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": "TABLET, CHEWABLE",
      "route": "ORAL",
      "marketing_status": "Prescription",
      "codes": {
        "rxcui": null,
        "mesh": "D010672",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "FDA_NDA",
          "code": "ANDA200565",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D010672",
          "display": "Phenytoin"
        }
      ],
      "context": " equal numbers. The exact incidence and prevalence of the disorder is unknown. Studies have suggested that approximately 5%-10% of infants exposed to phenytoin during pregnancy will develop fetal hydantoin syndrome. There is no diagnostic testing that can identify fetal hydantoin syndrome. A diagnosis is mad",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_fda_approved_drugs.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "fosphenytoin",
        "phenytoin dihydrodiol",
        "3-(hydroxymethyl)phenytoin"
      ],
      "pubtator_normalized_name": "Phenytoin",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "hydantoin",
      "preferred_name": "hydantoin",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": "D006827",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "RxCUI",
          "code": "1721294",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D006827",
          "display": "Hydantoins"
        }
      ],
      "context": "Fetal hydantoin syndrome affects males and females in equal numbers. The exact incidence and prevalence of the disorder is unknown. Studies have suggested that appro",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_lexicon_drug.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "iprodione",
        "hydantoin-5-propionic acid",
        "BW 245C"
      ],
      "pubtator_normalized_name": "Hydantoins",
      "enrichment_source": "pubtator3"
    }
  ]
}